Medical Center Hera EOOD - Clinic/Outpatient Facility
Sofia, 1510, Bulgaria
NCT Number: NCT04295941
The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, for up to 24 weeks.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Sofia, 1510, Bulgaria
This is an observational, prospective, single group, multicentre, international study.
The present study is planned to assess, in a real-world setting, the long-term clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who, according to the physician's judgment, have responded to the acute monotherapy (6 to 8 weeks of treatment) with Trazodone once-a-day and are eligible to continue Trazodone once-a-day monotherapy according to clinical practice.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Male and female patients of any ethnic origin ≥18 years old at Baseline. Outpatients who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 or the International Classification of Diseases (ICD)-10 criteria for MDD as their primary diagnosis and presenting with an episode of MDD.
Patients judged as responders to the acute monotherapy with TzOAD after a minimum of 6 and a maximum of 8 weeks of treatment and who are eligible to continue the assigned monotherapy according to the physician's judgement.
Patients legally capable of giving their written consent for participation in the study and for personal data processing and willing to comply with all study procedures.
Exclusion criteria
Patients that meet any of the contraindications to the administration of TzOAD according to the approved SmPC.
Patients with previous or current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, dysthymic or adjustment disorders, mental retardation, organic mental disorders or mental disorders due to a general medical condition.
Patients with previous or current history of a clinically significant neurological disorder, or any neurodegenerative diseases that might compromise the participation in the study.
Patients who are, according to the physician's judgement, at serious risk of suicide.
Patients with substance abuse or dependence (except nicotine dependence), as defined by DSM-5.
Patients participating in any pharmacological or non-pharmacological interventional study.
Oral administration of Trazodone once-a-day.
Time frame: 24(+4) weeks
The clinical response expressed as CGI-I responders' percentage at 24 (+ 4) weeks.
Time frame: 12 (+ 3) weeks.
The clinical response expressed as CGI-I responders' percentage at 12 (+ 3) weeks.
Time frame: 18 (+ 3) weeks
The clinical response expressed as CGI-I responders' percentage at 18 (+ 3) weeks.
Time frame: 24-week period
The functional impairment evaluated over the 24-week period
Time frame: 24-week period
The quality of life evaluated over the 24-week period
Aziende Chimiche Riunite Angelini Francesco S.p.A
Industry
Long-term Treatment With Trazodone Once-a-Day (TzOAD) in Patients With MDD: an Observational, Prospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial Details